Showing 1 - 10 of 5,554
, distribution and trade in pharmaceuticals and related supplies are subject to government regulatory control at a number of levels … differential regulation may unnecessarily hinder the cross-border movement of pharmaceuticals, particularly among regions that … include chapters covering intellectual property rights and regulatory data with respect to pharmaceuticals, as well as …
Persistent link: https://www.econbiz.de/10014133283
Multinational pharmaceutical corporations are searching for means to broaden their capacity for drug development while decreasing costs. Pharmaceutical firms in India and China are increasingly forging partnerships with these corporations to gain revenue and to develop their own expertise. These...
Persistent link: https://www.econbiz.de/10014047447
We consider how patent rights and price regulation affect whether new drugs are marketed in a country, and how quickly. The analysis covers a large sample of 68 countries at all income levels and includes all drug launches over the period 1982-2002. It uses newly compiled information on legal...
Persistent link: https://www.econbiz.de/10014049259
We consider how patent rights and price regulation affect whether new drugs are marketed in a country, and how quickly. The analysis covers a large sample of 68 countries at all income levels and includes all drug launches over the period 1982-2002. It uses newly compiled information on legal...
Persistent link: https://www.econbiz.de/10014219250
Efforts to strengthen the global patent system for pharmaceuticals continue to be controversial, and what will likely … investment in medical research, the availability of the resulting therapies, how the financial burdens are distributed across …
Persistent link: https://www.econbiz.de/10013224385
We consider how patent rights and price regulation affect whether new drugs are marketed in a country, and how quickly. The analysis covers a large sample of 68 countries at all income levels and includes all drug launches over the period 1982-2002. It uses newly compiled information on legal...
Persistent link: https://www.econbiz.de/10014026156
Persistent link: https://www.econbiz.de/10013490222
When the Medicare program was created in 1965, outpatient prescription drugs were left out of the benefit package, a decision that maintained consistency with standard private insurance plans of the time. Cost was one factor behind the exclusion, but a more fundamental reason related to the role...
Persistent link: https://www.econbiz.de/10013229909
Persistent link: https://www.econbiz.de/10003349635
Persistent link: https://www.econbiz.de/10003415449